Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360174 · ClinicalTrials.gov registry record · Phase 1
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04360174 is a Phase 1 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 19 participants.
The verdict
NCT04360174, a Phase 1 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG OTX-TIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2021-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04360174
The ClinicalTrials.gov registry entry for NCT04360174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTX-TIC is the first listed.
NCT04360174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04360174 about?
NCT04360174 is a clinical study titled "CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension". To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT04360174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-04-25. Estimated completion is 2021-05-24.
What interventions are being tested in trial NCT04360174?
The interventions under investigation include: OTX-TIC (DRUG).
Who is sponsoring clinical trial NCT04360174?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.